Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target: Broad ORGS Patent for Turning Liver Cells into Insulin Producing Cells Creates a Potential Cure for Diabetes
Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target
Initiating Coverage on Orgenesis, Inc. (ORGS) with $2.50 12-18 Month Target: Broad ORGS Patent for Turning Liver Cells into Insulin Producing Cells Creates a Potential Cure for Diabetes
Ticker: ORGS: OTCQB
Website: http://www.orgenesis.com/
Fully Diluted Shares Outstanding: 55.2 Million
Float: 23.5 million
Average Trading Volume: 21,000
Market Capitalization: $32 Million
Current Share Price: .60
52-Week High/Low: $1.00/.34
12-18 Month Target: $2.50 based on 2016E revenues of 7 cents a share and Phase 1 clinical trial initiation within 12-15 months.
The Company: Orgenesis, Inc. (ORGS) is a biotechnology leader in the research, development and commercialization of reprogramming human liver cells into glucose responsive, fully-functional Insulin Producing Cells (IPCs).
Investment Thesis: The Company’s broad method of use patent for cellular trans-differentiation “Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet tissues” awarded October 15, 2014 puts ORGS in the lead position for a Phase 1 Clinical Trial in 12-15 months with a practical cure for Type 1 and Type 2 insulin resistant diabetes by 2018-2020.
Target: $2.50 12-18 month target is based on the closing of lab transaction and 7 cents revenue per share fully diluted and Phase 1 trial initiation in 12-15 months.
Click here to view the complete report.
Founder and Editor-in-Chief for NBTEquitiesResearch.com. Contributor and Anchor for the Fox News Channel and Fox Business Network 2000-2013. Chairman & CEO of NBT Group, Inc., a boutique private capital investment bank and investor relations organization.
- Login to post comments
